Mitochondrial membrane potential and reactive oxygen species in cancer stem cells

Familial Cancer

Volumn 14, Issue 1, 2015, Pages 19-23

  Zhang, Bei bei ^a   Wang, Dao gang ^b   Guo, Fen fen ^c   Xuan, Chao ^d  

^a MIE UNIVERSITY   (Japan)

^b THE FIRST AFFILIATED HOSPITAL OF GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

^c QINGDAO WOMEN AND CHILDREN S HOSPITAL   (China)

^d QINGDAO UNIVERSITY   (China)

Author keywords

Cancer stem cells; Mitochondrial membrane potential; Reactive oxygen species

Indexed keywords

REACTIVE OXYGEN METABOLITE;

A549 CELL LINE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; EPITHELIUM CELL; FUNCTIONAL STATUS; GLIOBLASTOMA CELL LINE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MCF 7 CELL LINE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PULMONARY ARTERY SMOOTH MUSCLE CELL; REVIEW; METABOLISM; PATHOLOGY; PHYSIOLOGY;

HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASTIC STEM CELLS; REACTIVE OXYGEN SPECIES;

EID: 84939202287     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-014-9757-9     Document Type: Review

References (54)

1. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755–768. doi:10.1038/nrc2499
2. Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26(17):2839–2845. doi:10.1200/JCO.2007.15.1829
3. Dayem AA, Choi HY, Kim JH, Cho SG (2010) Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers 2(2):859–884. doi:10.3390/cancers2020859
4. Shmelkov SV, St Clair R, Lyden D, Rafii S (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37(4):715–719. doi:10.1016/j.biocel.2004.08.010
5. Mimeault M, Hauke R, Mehta PP, Batra SK (2007) Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11(5):981–1011. doi:10.1111/j.1582-4934.2007.00088.x
6. Kai K, Arima Y, Kamiya T, Saya H (2010) Breast cancer stem cells. Breast Cancer 17(2):80–85. doi:10.1007/s12282-009-0176-y
7. Zhang M, Rosen JM (2006) Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 16(1):60–64. doi:10.1016/j.gde.2005.12.008
8. Gerber JM, Qin L, Kowalski J et al (2011) Characterization of chronic myeloid leukemia stem cells. Am J Hematol 86(1):31–37. doi:10.1002/ajh.21915
9. Fleischman AG (2012) ALDH marks leukemia stem cell. Blood 119(15):3376–3377. doi:10.1182/blood-2012-02-406751
10. Schimmer AD, O’Brien S, Kantarjian H et al (2008) A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14(24):8295–8301. doi:10.1158/1078-0432.CCR-08-0999
11. Brenner C, Kroemer G (2000) Mitochondria: the death signal integrators. Science 289(5482):1150–1151
12. Gogvadze V, Orrenius S, Zhivotovsky B (2008) Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18(4):165–173. doi:10.1016/j.tcb.2008.01.006
13. Modica-Napolitano JS, Singh KK (2004) Mitochondrial dysfunction in cancer. Mitochondrion 4(5–6):755–762. doi:10.1016/j.mito.2004.07.027
14. Ye XQ, Li Q, Wang GH et al (2011) Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer Journal international du cancer 129(4):820–831. doi:10.1002/ijc.25944
15. Diehn M, Cho RW, Lobo NA et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239):780–783. doi:10.1038/nature07733
16. Lonergan T, Bavister B, Brenner C (2007) Mitochondria in stem cells. Mitochondrion 7(5):289–296. doi:10.1016/j.mito.2007.05.002
17. Lonergan T, Brenner C, Bavister B (2006) Differentiation-related changes in mitochondrial properties as indicators of stem cell competence. J Cell Physiol 208(1):149–153. doi:10.1002/jcp.20641
18. Bonnet S, Archer SL, Allalunis-Turner J et al (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11(1):37–51. doi:10.1016/j.ccr.2006.10.020
19. Chen LB (1988) Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4:155–181. doi:10.1146/annurev.cb.04.110188.001103
20. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13(6):472–482. doi:10.1016/j.ccr.2008.05.005
21. Hockenbery DM (2002) A mitochondrial Achilles’ heel in cancer? Cancer Cell 2(1):1–2
22. Yu M, Shi Y, Wei X et al (2007) Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of T47D human breast cancer cells. Toxicol Lett 170(1):83–93. doi:10.1016/j.toxlet.2007.02.013
23. Schieke SM, Ma M, Cao L et al (2008) Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells. J Biol Chem 283(42):28506–28512. doi:10.1074/jbc.M802763200
24. Heerdt BG, Houston MA, Wilson AJ, Augenlicht LH (2003) The intrinsic mitochondrial membrane potential (Deltapsim) is associated with steady-state mitochondrial activity and the extent to which colonic epithelial cells undergo butyrate-mediated growth arrest and apoptosis. Cancer Res 63(19):6311–6319
25. Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67(10):4827–4833. doi:10.1158/0008-5472.CAN-06-3557
26. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH (2007) Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67(8):3716–3724. doi:10.1158/0008-5472.CAN-06-4343
27. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res 65(14):6207–6219. doi:10.1158/0008-5472.CAN-05-0592
28. Hirschmann-Jax C, Foster AE, Wulf GG et al (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101(39):14228–14233. doi:10.1073/pnas.0400067101
29. Derdak Z, Fulop P, Sabo E et al (2006) Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. Carcinogenesis 27(5):956–961. doi:10.1093/carcin/bgi335
30. Pecqueur C, Bui T, Gelly C et al (2008) Uncoupling protein-2 controls proliferation by promoting fatty acid oxidation and limiting glycolysis-derived pyruvate utilization. FASEB Journal 22(1):9–18. doi:10.1096/fj.07-8945com
31. Wasilewski M, Scorrano L (2009) The changing shape of mitochondrial apoptosis. Trends Endocrinol Metab TEM 20(6):287–294. doi:10.1016/j.tem.2009.03.007
32. Pietila M, Lehtonen S, Narhi M et al (2010) Mitochondrial function determines the viability and osteogenic potency of human mesenchymal stem cells. Tissue Eng Part C Methods 16(3):435–445. doi:10.1089/ten.tec.2009.0247
33. Yajima T, Ochiai H, Uchiyama T, Takano N, Shibahara T, Azuma T (2009) Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int J Oncol 35(2):273–280
34. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003) Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160(2):189–200. doi:10.1083/jcb.200211046
35. Levraut J, Iwase H, Shao ZH, Vanden Hoek TL, Schumacker PT (2003) Cell death during ischemia: relationship to mitochondrial depolarization and ROS generation. Am J Physiol Heart Circ Physiol 284(2):H549–H558. doi:10.1152/ajpheart.00708.2002
36. Klein BY, Gal I, Libergal M, Ben-Bassat H (1996) Opposing effects on mitochondrial membrane potential by malonate and levamisole, whose effect on cell-mediated mineralization is antagonistic. J Cell Biochem 60(1):139–147. doi:10.1002/(SICI)1097-4644(19960101)60:1<139:AID-JCB16>3.0.CO;2-K
37. Shi X, Zhang Y, Zheng J, Pan J (2012) Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 16(11):1215–1228. doi:10.1089/ars.2012.4529
38. Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51(3):794–798
39. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8(7):579–591. doi:10.1038/nrd2803
40. Liu L, Chen R, Huang S et al (2011) Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. Med Oncol 28(3):835–839. doi:10.1007/s12032-010-9529-9
41. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF (2010) Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 107(8):3722–3727. doi:10.1073/pnas.0915135107
42. Kim YS, Kang MJ, Cho YM (2013) Low production of reactive oxygen species and high DNA repair: mechanism of radioresistance of prostate cancer stem cells. Anticancer Res 33(10):4469–4474
43. Kong Q, Lillehei KO (1998) Antioxidant inhibitors for cancer therapy. Med Hypotheses 51(5):405–409
44. Guzman ML, Li X, Corbett CA et al (2007) Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 110(13):4436–4444. doi:10.1182/blood-2007-05-088815
45. Guzman ML, Rossi RM, Karnischky L et al (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105(11):4163–4169. doi:10.1182/blood-2004-10-4135
46. Jin Y, Lu Z, Ding K et al (2010) Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 70(6):2516–2527. doi:10.1158/0008-5472.CAN-09-3950
47. Yahata T, Muguruma Y, Yumino S et al (2008) Quiescent human hematopoietic stem cells in the bone marrow niches organize the hierarchical structure of hematopoiesis. Stem Cells 26(12):3228–3236. doi:10.1634/stemcells.2008-0552
48. Ito K, Bernardi R, Morotti A et al (2008) PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453(7198):1072–1078. doi:10.1038/nature07016
49. Abdel-Wahab O, Levine RL (2010) Metabolism and the leukemic stem cell. J Exp Med 207(4):677–680. doi:10.1084/jem.20100523
50. Biasutto L, Dong LF, Zoratti M, Neuzil J (2010) Mitochondrially targeted anti-cancer agents. Mitochondrion 10(6):670–681. doi:10.1016/j.mito.2010.06.004
51. Smith RA, Hartley RC, Murphy MP (2011) Mitochondria-targeted small molecule therapeutics and probes. Antioxid Redox Signal 15(12):3021–3038. doi:10.1089/ars.2011.3969
52. Modica-Napolitano JS, Aprille JR (1987) Basis for the selective cytotoxicity of rhodamine 123. Cancer Res 47(16):4361–4365
53. Modica-Napolitano JS, Nalbandian R, Kidd ME, Nalbandian A, Nguyen CC (2003) The selective in vitro cytotoxicity of carcinoma cells by AZT is enhanced by concurrent treatment with delocalized lipophilic cations. Cancer Lett 198(1):59–68
54. Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P (2002) A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2(1):29–42